• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Expert and lay perspectives on burden, risk, tolerability, and acceptability of clinical interventions for genetic disorders.专家和非专业人士对遗传疾病临床干预的负担、风险、耐受性和可接受性的看法。
Genet Med. 2019 Nov;21(11):2561-2568. doi: 10.1038/s41436-019-0524-z. Epub 2019 Apr 26.
2
Evidence-based assessments of clinical actionability in the context of secondary findings: Updates from ClinGen's Actionability Working Group.基于证据的二次发现临床可操作性评估:ClinGen 可操作性工作组的最新进展。
Hum Mutat. 2018 Nov;39(11):1677-1685. doi: 10.1002/humu.23631.
3
A standardized, evidence-based protocol to assess clinical actionability of genetic disorders associated with genomic variation.一种用于评估与基因组变异相关的遗传疾病临床可操作性的标准化、循证方案。
Genet Med. 2016 Dec;18(12):1258-1268. doi: 10.1038/gim.2016.40. Epub 2016 Apr 28.
4
A semiquantitative metric for evaluating clinical actionability of incidental or secondary findings from genome-scale sequencing.一种用于评估基因组规模测序中偶然发现或次要发现的临床可操作性的半定量指标。
Genet Med. 2016 May;18(5):467-75. doi: 10.1038/gim.2015.104. Epub 2015 Aug 13.
5
Implementing evidence-based assertions of clinical actionability in the context of secondary findings: Updates from the ClinGen Actionability Working Group.在二次发现的背景下实施临床可操作性的循证主张:ClinGen 可操作性工作组的最新进展。
Genet Med. 2024 Aug;26(8):101164. doi: 10.1016/j.gim.2024.101164. Epub 2024 May 14.
6
Public perceptions of disease severity but not actionability correlate with interest in receiving genomic results: nonalignment with current trends in practice.公众对疾病严重程度而非可操作性的认知与接受基因检测结果的意愿相关:与当前的实际趋势不一致。
Public Health Genomics. 2015;18(3):173-83. doi: 10.1159/000375479. Epub 2015 Mar 12.
7
ClinGen's Pediatric Actionability Working Group: Clinical actionability of secondary findings from genome-scale sequencing in children and adolescents.ClinGen 儿科可操作性工作组:儿童和青少年全基因组测序中二级发现的临床可操作性。
Genet Med. 2022 Jun;24(6):1328-1335. doi: 10.1016/j.gim.2022.02.019. Epub 2022 Mar 25.
8
Public knowledge of and attitudes toward genetics and genetic testing.公众对遗传学和基因检测的了解及态度。
Genet Test Mol Biomarkers. 2013 Apr;17(4):327-35. doi: 10.1089/gtmb.2012.0350. Epub 2013 Feb 13.
9
Actionability of unanticipated monogenic disease risks in newborn genomic screening: Findings from the BabySeq Project.新生儿基因组筛查中未预料到的单基因疾病风险的可操作性:BabySeq 项目的研究结果。
Am J Hum Genet. 2023 Jul 6;110(7):1034-1045. doi: 10.1016/j.ajhg.2023.05.007. Epub 2023 Jun 5.
10
Harmonizing Outcomes for Genomic Medicine: Comparison of eMERGE Outcomes to ClinGen Outcome/Intervention Pairs.协调基因组医学的结果:eMERGE结果与ClinGen结果/干预对的比较。
Healthcare (Basel). 2018 Jul 13;6(3):83. doi: 10.3390/healthcare6030083.

引用本文的文献

1
Modelling Population Genetic Screening in Rare Neurodegenerative Diseases.罕见神经退行性疾病的群体基因筛查建模
Biomedicines. 2025 Apr 23;13(5):1018. doi: 10.3390/biomedicines13051018.
2
The Clinical Genome Resource (ClinGen): Advancing genomic knowledge through global curation.临床基因组资源(ClinGen):通过全球整理推进基因组学知识。
Genet Med. 2025 Jan;27(1):101228. doi: 10.1016/j.gim.2024.101228. Epub 2024 Oct 15.
3
Implementing evidence-based assertions of clinical actionability in the context of secondary findings: Updates from the ClinGen Actionability Working Group.在二次发现的背景下实施临床可操作性的循证主张:ClinGen 可操作性工作组的最新进展。
Genet Med. 2024 Aug;26(8):101164. doi: 10.1016/j.gim.2024.101164. Epub 2024 May 14.
4
Establishing the Medical Actionability of Genomic Variants.建立基因组变异的医学可操作性。
Annu Rev Genomics Hum Genet. 2022 Aug 31;23:173-192. doi: 10.1146/annurev-genom-111021-032401. Epub 2022 Apr 1.
5
ClinGen's Pediatric Actionability Working Group: Clinical actionability of secondary findings from genome-scale sequencing in children and adolescents.ClinGen 儿科可操作性工作组:儿童和青少年全基因组测序中二级发现的临床可操作性。
Genet Med. 2022 Jun;24(6):1328-1335. doi: 10.1016/j.gim.2022.02.019. Epub 2022 Mar 25.
6
Guidelines for Genetic Testing and Management of Alport Syndrome.《Alport 综合征的基因检测与管理指南》。
Clin J Am Soc Nephrol. 2022 Jan;17(1):143-154. doi: 10.2215/CJN.04230321. Epub 2021 Dec 20.

专家和非专业人士对遗传疾病临床干预的负担、风险、耐受性和可接受性的看法。

Expert and lay perspectives on burden, risk, tolerability, and acceptability of clinical interventions for genetic disorders.

机构信息

Center for Communication Science, RTI International, Research Triangle Park, NC, USA.

Center for Health Research, Kaiser Permanente Northwest, Portland, OR, USA.

出版信息

Genet Med. 2019 Nov;21(11):2561-2568. doi: 10.1038/s41436-019-0524-z. Epub 2019 Apr 26.

DOI:10.1038/s41436-019-0524-z
PMID:31028355
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6815237/
Abstract

PURPOSE

The Clinical Genome Resource (ClinGen) Actionability Working Group (AWG) developed a semiquantitative scoring metric to rate clinical actionability of genetic disorders and associated genes in four domains: (1) severity of the outcome, (2) likelihood of the outcome, (3) effectiveness of the intervention to prevent/minimize the outcome, and (4) nature of the intervention with respect to burden, risk, tolerability, and acceptability to the patient. This study aimed to assess whether nature of the intervention scores assigned by AWG experts reflected lay perceptions of intervention burden, risk, tolerability, and acceptability given the subjectivity of this domain.

METHODS

In July 2017, a general population sample of 1344 adults completed the study. Each participant was asked to read 1 of 24 plain language medical intervention synopses and answer questions related to its burden, risk, tolerability, and acceptability. We conducted three multilevel mixed model analyses predicting the perceived burden, perceived risk, and perceived overall nature of the intervention.

RESULTS

As AWG nature of the intervention scores increased, lay perceptions of intervention burden and risk decreased, and perceptions of tolerability and acceptability increased.

CONCLUSION

The findings show alignment between the ClinGen actionability scoring metric and lay perceptions of the nature of the intervention.

摘要

目的

临床基因组资源(ClinGen)可操作性工作组(AWG)开发了一种半定量评分指标,用于评估四个领域中遗传疾病和相关基因的临床可操作性:(1)结果的严重程度,(2)结果的可能性,(3)预防/最小化结果的干预措施的有效性,以及(4)干预措施的性质,包括负担、风险、耐受性和对患者的可接受性。本研究旨在评估 AWG 专家分配的干预性质评分是否反映了患者对干预负担、风险、耐受性和可接受性的看法,因为该领域具有主观性。

方法

在 2017 年 7 月,一个由 1344 名成年人组成的普通人群样本完成了这项研究。每个参与者都被要求阅读 24 个普通语言医疗干预摘要中的 1 个,并回答与其负担、风险、耐受性和可接受性相关的问题。我们进行了三项多级混合模型分析,预测感知的干预负担、感知的风险和感知的干预整体性质。

结果

随着 AWG 干预性质评分的增加,患者对干预负担和风险的看法降低,对耐受性和可接受性的看法增加。

结论

这些发现表明 ClinGen 可操作性评分指标与患者对干预性质的看法一致。